Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20214216 | 0.88 | HDAC3 (0.64) | RAB9ANPC1HDAC1HDAC8HDAC6 | |
| SCHEMBL20214231 | 0.83 | RAB9A (0.71) | RAB9ANPC1LMNAALDH1A1MAPT | |
| SCHEMBL20214236 | 0.78 | NFE2L2 (0.54) | RAB9ANPC1HDAC1HDAC8HDAC6 | |
| SCHEMBL20214237 | 0.78 | NFE2L2 (0.54) | RAB9ANPC1HDAC1HDAC8HDAC6 | |
| SCHEMBL6536150 | 0.77 | RAB9A (0.73) | RAB9ANPC1HDAC1HDAC8HDAC6 | |
| SCHEMBL20214809 | 0.77 | CA1 (0.46) | RAB9ANPC1TDP1SMPD1NR1H4 | |
| SCHEMBL20214800 | 0.74 | HDAC6 (0.67) | RAB9ANPC1NR1H4HDAC1HDAC8 | |
| SCHEMBL28961053 | 0.73 | CYP1A2 (0.63) | NR1H4HDAC3HDAC2CYP3A4TSHR | |
| SCHEMBL29412632 | 0.73 | CYP1A2 (0.63) | RAB9ANPC1NR1H4HDAC3HDAC2 | |
| SCHEMBL2446906 | 0.73 | CYP1A2 (0.63) | RAB9ANPC1NR1H4HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181175-A1 | BORONIC DERIVATIVES OF HYDROXAMATES AS ANTICANCER AGENTS | XAVIER UNIVERSITY OF LOUISIANA | 2020-06-11 | — | — | US | claimed |
| WO-2018102261-A2 | BORONIC DERIVATIVES HYDROXAMATES AS ANTICANCER AGENTS | XAVIER UNIVERSITY OF LOUISIANA (US) | 2018-06-07 | — | — | WO | claimed |
| US-11046715-B2 | Boronic derivatives of hydroxamates as anticancer agents | XAVIER UNIVERSITY OF LOUISIANA (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200181175-A1 | BORONIC DERIVATIVES OF HYDROXAMATES AS ANTICANCER AGENTS | XAVIER UNIVERSITY OF LOUISIANA | 2020-06-11 | — | — | US | disclosed |
| WO-2018102261-A2 | BORONIC DERIVATIVES HYDROXAMATES AS ANTICANCER AGENTS | XAVIER UNIVERSITY OF LOUISIANA (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181175-A1 | BORONIC DERIVATIVES OF HYDROXAMATES AS ANTICANCER AGENTS | BCOR, BRDT, HDAC1 | RAB9A 3029/4885NPC1 801/4885TDP1 402/4885 |
| US-11046715-B2 | Boronic derivatives of hydroxamates as anticancer agents | BCOR, BRDT, HDAC1 | RAB9A 3029/4885NPC1 801/4885TDP1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.